

# Medlab Clinical Ltd

03:01 04 Jul 2019

## Medlab Clinical achieves over \$3 million revenue for June quarter, shares rise

Medlab Clinical Ltd (ASX:MDC) achieved total revenue in excess of \$3 million for the June quarter representing a 135% increase on last year's June quarter.

On the research front, Medlab is focused on chronic disease markets including pain management and depression where global markets represent significant earnings opportunities.

Medlab's patented nutraceutical product in the market, NRGBiotic™, is being evaluated as a treatment for the gut and depression - progress is steady with encouraging early data.

Research work is also progressing using its patented cannabis-based medicines NanaBis™ and NanaBidial™, which also continues to yield strong, encouraging results.

Converting research and product development into commercial success

In both nutraceutical and medical cannabis categories, significant progress has been made commercialising products through increased sales.

Medlab has its own growing distribution team together with third party distributors where appropriate to maximise the potential global market penetration.

Product range can be found in over 3,000 Australian pharmacies

Medlab's CEO Dr Sean Hall said: "it's apparent that a number of our clients remember me from when I coowned and managed BioCeuticals.

"Although BioCeuticals was sold several years ago, this time has given me the ability to leverage solid research into the Medlab nutraceutical range and I believe this is what sets us apart from other ranges."

READ: Medlab Clinical signs distribution deal for NanaBis

In late May 2019, Medlabs executed a heads of agreement with Thai-listed Mega Lifesciences (BKK:MEGA) for the further global distribution of NanaBis™.

The terms of the Heads of Agreement provide for both parties to negotiate various commercial terms involving potential global territories for NanaBis™.

NanaBis is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

It is delivered into the body using Medlab's patented sub-micron delivery platform NanoCelle™.

**Price:** 0.305

**Market Cap:** \$71.13 m

### 1 Year Share Price Graph



### Share Information

**Code:** MDC

**Listing:** ASX

**52 week High Low**  
0.56 0.285

**Sector:** Cannabis

**Website:** www.medlab.co

### Company Synopsis:

Medlab Clinical Ltd (ASX:MDC) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

NanaBis is a buccal (side of cheek) spray currently in the second stage of an Australian advanced cancer pain trial.

Patients can access it under the government's Special Access Scheme and it is currently before several regulatory agencies for potential fast track drug approval pathways.

**READ: Medlab Clinical receives human ethics approval for cannabis-based pain management medicine trial**

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidual™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidual™ has a 18:2 ratio of CBD:THC.

NanaBis™ is currently in clinical trial at Royal North Shore Hospital.

Notably, both medicines are available to Australian patients for compassionate use under the government Special Access Scheme (SAS).

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).